In MM, it is associated with poor prognosis27, progression from monoclonal gammopathy of undetermined significance to active multiple myeloma27, and XPO1 was thought to be potentially biomarker of cancer progression as well as development of drug resistance in MM28. The gene discussed is XPO1; the disease is Miyoshi myopathy.